Temporospatial genomic profiling in glioblastoma identifies commonly altered core pathways underlying tumor progression.
PI3K signaling
clonal evolution
contrast enhancement
glioblastoma
temporospatial heterogeneity
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Historique:
entrez:
4
8
2020
pubmed:
4
8
2020
medline:
4
8
2020
Statut:
epublish
Résumé
Tumor heterogeneity underlies resistance and disease progression in glioblastoma (GBM), and tumors most commonly recur adjacent to the surgical resection margins in contrast non-enhancing (NE) regions. To date, no targeted therapies have meaningfully altered overall patient survival in the up-front setting. The aim of this study was to characterize intratumoral heterogeneity in recurrent GBM using bulk samples from primary resection and recurrent samples taken from contrast-enhancing (EN) and contrast NE regions. Whole exome and RNA sequencing were performed on matched bulk primary and multiple recurrent EN and NE tumor samples from 16 GBM patients who received standard of care treatment alone or in combination with investigational clinical trial regimens. Private mutations emerge across multi-region sampling in recurrent tumors. Genomic clonal analysis revealed increased enrichment in gene alterations regulating the G2M checkpoint, Kras signaling, Wnt signaling, and DNA repair in recurrent disease. Subsequent functional studies identified augmented PI3K/AKT transcriptional and protein activity throughout progression, validated by phospho-protein levels. Moreover, a mesenchymal transcriptional signature was observed in recurrent EN regions, which differed from the proneural signature in recurrent NE regions. Subclonal populations observed within bulk resected primary GBMs transcriptionally evolve across tumor recurrence (EN and NE regions) and exhibit aberrant gene expression of common signaling pathways that persist despite standard or targeted therapy. Our findings provide evidence that there are both adaptive and clonally mediated dependencies of GBM on key pathways, such as the PI3K/AKT axis, for survival across recurrences.
Sections du résumé
BACKGROUND
BACKGROUND
Tumor heterogeneity underlies resistance and disease progression in glioblastoma (GBM), and tumors most commonly recur adjacent to the surgical resection margins in contrast non-enhancing (NE) regions. To date, no targeted therapies have meaningfully altered overall patient survival in the up-front setting. The aim of this study was to characterize intratumoral heterogeneity in recurrent GBM using bulk samples from primary resection and recurrent samples taken from contrast-enhancing (EN) and contrast NE regions.
METHODS
METHODS
Whole exome and RNA sequencing were performed on matched bulk primary and multiple recurrent EN and NE tumor samples from 16 GBM patients who received standard of care treatment alone or in combination with investigational clinical trial regimens.
RESULTS
RESULTS
Private mutations emerge across multi-region sampling in recurrent tumors. Genomic clonal analysis revealed increased enrichment in gene alterations regulating the G2M checkpoint, Kras signaling, Wnt signaling, and DNA repair in recurrent disease. Subsequent functional studies identified augmented PI3K/AKT transcriptional and protein activity throughout progression, validated by phospho-protein levels. Moreover, a mesenchymal transcriptional signature was observed in recurrent EN regions, which differed from the proneural signature in recurrent NE regions.
CONCLUSIONS
CONCLUSIONS
Subclonal populations observed within bulk resected primary GBMs transcriptionally evolve across tumor recurrence (EN and NE regions) and exhibit aberrant gene expression of common signaling pathways that persist despite standard or targeted therapy. Our findings provide evidence that there are both adaptive and clonally mediated dependencies of GBM on key pathways, such as the PI3K/AKT axis, for survival across recurrences.
Identifiants
pubmed: 32743548
doi: 10.1093/noajnl/vdaa078
pii: vdaa078
pmc: PMC7388612
doi:
Types de publication
Journal Article
Langues
eng
Pagination
vdaa078Informations de copyright
© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Cancer Cell. 2019 Apr 15;35(4):692-704.e12
pubmed: 30905762
Genome Biol. 2011;12(4):R41
pubmed: 21527027
Nat Genet. 2016 Jul;48(7):768-76
pubmed: 27270107
Cancer Cell. 2017 Jul 10;32(1):42-56.e6
pubmed: 28697342
Ann Oncol. 2019 Mar 1;30(3):456-463
pubmed: 30452544
J Clin Oncol. 2019 Mar 20;37(9):741-750
pubmed: 30715997
PLoS Comput Biol. 2016 Apr 21;12(4):e1004873
pubmed: 27100738
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Nat Genet. 2017 Apr;49(4):594-599
pubmed: 28263318
Nucleic Acids Res. 2016 Jun 20;44(11):e108
pubmed: 27060149
Clin Neurol Neurosurg. 2013 Jan;115(1):37-43
pubmed: 22537870
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
J Neurooncol. 2019 Feb;141(3):523-531
pubmed: 30644009
Nature. 2019 Dec;576(7785):112-120
pubmed: 31748746
Commun Biol. 2019 Apr 23;2:135
pubmed: 31044160
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
J Clin Oncol. 2020 Jan 1;38(1):81-99
pubmed: 31743054
F1000Res. 2014 Jul 01;3:141
pubmed: 25075306
Nucleic Acids Res. 2016 Jan 4;44(D1):D481-7
pubmed: 26656494
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
PLoS One. 2017 Jan 19;12(1):e0169292
pubmed: 28103256
AJNR Am J Neuroradiol. 2019 May;40(5):758-765
pubmed: 30948373
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
Front Oncol. 2019 Mar 20;9:119
pubmed: 30949446
J Neurosurg. 2016 Dec;125(Suppl 1):40-49
pubmed: 27903197
Clin Cancer Res. 2018 Jan 15;24(2):295-305
pubmed: 29074604
Clin Cancer Res. 2009 Jul 15;15(14):4622-9
pubmed: 19584161
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Br J Cancer. 2010 Oct 12;103(8):1139-43
pubmed: 20877357
Cancer Res. 2006 Apr 15;66(8):3987-91
pubmed: 16618716
Nature. 2018 Jan 11;553(7687):222-227
pubmed: 29323298
Cancer Cell. 2006 Mar;9(3):157-73
pubmed: 16530701
Nucleic Acids Res. 2018 Apr 20;46(7):e39
pubmed: 29361062
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Neuro Oncol. 2018 Jan 22;20(2):184-191
pubmed: 29016900
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931